Skip to main content

Danaher Prices $2.76B Offering of Common, Preferred Stock

NEW YORK (GenomeWeb) – Danaher said after the close of the market on Tuesday that it has priced its concurrent public offering of common stock and mandatory convertible preferred stock.

The company is offering 11 millionshares of its common stock at $123 per share and 1.5 million shares of its 4.75 percent Series A Mandatory Convertible Preferred Stock at $1,000 per share. The underwriters have separate 30-day options to purchase up to an additional 1.1 million shares of common stock and up to an additional 150,000 shares of mandatory convertible preferred stock.

Barclays and Goldman Sachs are the representatives of the underwriters and joint book-running managers for the offerings. Credit Suisse and HSBC also are joint book-running managers.

Net proceeds from the common stock offering is expected to be about $1.31 billion, and net proceeds from the mandatory convertible preferred stock offering is expected to be about $1.45 billion. If the underwriters exercise their options in full, net proceeds from the common stock offering are anticipated to be approximately $1.44 billion and net proceeds from the mandatory convertible preferred stock are anticipated to be about $1.60 billion.

Danaher intends to use the financing to fund a portion of its proposed $21.4 billion acquisition of GE Biopharma. The offerings are expected to be completed on March 1.

In morning trading on the New York Stock Exchange, Danaher's shares rose more than 2 percent to $126.32.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.